Laura Donlin, PhD
About Dr. Donlin
Dr. Laura Donlin aims to deepen our understanding of autoimmune and musculoskeletal disorders by uncovering molecular patterns found within patient samples. The goal of this work is to create personalized treatment strategies based on patient-specific molecular signatures.
Working closely with HSS rheumatologists and surgeons, Dr. Donlin analyzes patient samples with cutting-edge molecular techniques such as next-generation sequencing. Combining these functional genomics analyses with drug response assays, Dr. Donlin looks to understand how the cellular and molecular profiles found within patient samples relate to treatment responses. Dr. Donlin and colleagues also use cell culture models to study how cells co-evolve during chronic inflammatory responses, with the intent of identifying novel therapeutic targets for autoimmune conditions such as rheumatoid arthritis.
The Donlin laboratory aims to increase understanding of the human immune system by analyzing patient samples with high-dimensional molecular technologies. Our projects are designed around clinical unmet needs of patients with autoimmune and musculoskeletal disorders.
We have projects focused on rheumatoid arthritis (RA) and an arthritis condition that results from immune checkpoint inhibitors that are used to treat cancer, as well as myositis, prosthetic joint infections and synovial tumors. Further, our multidisciplinary teams participate in the NIH-industry sponsored Accelerating Medicines Partnership (AMP) consortium that aims to identify novel drug targets in conditions such as RA, as well as the NIH Impact of Genomic Variation on Function (IGVF) consortium that examines how genetic and epigenetic differences impact human disease.
Through these collaborative projects, we aim to improve medical practice through basic science rigor and molecular-focused assays.
- Autoimmune diseases (eg. rheumatoid arthritis)
- Human immunology
- Molecular biology
Profile Video
Credentials
Appointments
Co-Director, HSS Precision Medicine Program
Principal Investigator, HSS Research Institute
Associate Professor, Weill Cornell Medical School and Graduate School
Education
PhD, Columbia University, New York, NY
Postdoctoral Training, Rockefeller University, New York, NY
Languages
EnglishIndustry Relationships
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Research staff at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however, HSS also believes that these collaborations must be disclosed. As part of the disclosure process, this website lists Research staff collaborations with outside companies if the Research staff member received any payment during the prior year or expects to receive any payment in the next year. The disclosures are based on information provided by the Research staff and other sources and are updated regularly. Current ownership interests and leadership positions are also listed. Further information may be available on individual company websites.
As of , Dr. Donlin reported no relationships with the healthcare industry.
By disclosing the collaborations of HSS Research staff with industry on this website, HSS and its Research staff make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit payment of royalties on products developed by him/her that are used on patients at HSS. Feel free to ask the Research staff member about their relationship(s).